BeiGene shares are trading lower after Novartis terminated licensing deal to develop, manufacture and commercialize ociperlimab.
Portfolio Pulse from Benzinga Newsdesk
Novartis has terminated its licensing deal with BeiGene to develop, manufacture and commercialize ociperlimab, causing BeiGene shares to trade lower.
July 11, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BeiGene's shares are trading lower after Novartis terminated its licensing deal with the company.
The termination of the licensing deal with Novartis, a major pharmaceutical company, is a significant setback for BeiGene. This could potentially affect the company's revenue and growth prospects, leading to a decrease in its share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100